Abstract:Chimeric antigen receptor (CAR) T-cell therapy has achieved notable success in treating hematological cancers but faces significant challenges in solid-tumor treatment and overall efficacy. Key limitations include T-cell exhaustion, tumor relapse, immunosuppressive tumor microenvironments (TME), immunogenicity, and antigen heterogeneity. To address these issues, various genetic engineering strategies have been proposed. Approaches such as overexpression of transcription factors or metabolic armoring and dynamic CAR regulation are being explored to improve CAR T-cell function and safety. Other efforts to improve CAR T-cell efficacy in solid tumors include targeting novel antigens or developing alternative strategies to address antigen diversity. Despite the promising preclinical results of these solutions, challenges remain in translating CAR T-cell therapies to the clinic to enable economically viable access to these transformative medicines. The efficiency and scalability of autologous CAR T-cell therapy production are hindered by traditional, manual processes which are costly, time-consuming, and prone to variability and contamination. These high-cost, time-intensive processes have complex quality-control requirements. Recent advancements suggest that smaller, decentralized solutions such as microbioreactors and automated point-of-care systems could improve production efficiency, reduce costs, and shorten manufacturing timelines, especially when coupled with innovative manufacturing methods such as transposons and lipid nanoparticles. Future advancements may include harmonized consumables and AI-enabled technologies, which promise to streamline manufacturing, reduce costs, and enhance production quality.

Augmenting the landscape of chimeric antigen receptor T-cell therapy

Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress

Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon

Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Advances in manufacturing chimeric antigen receptor immune cell therapies

Tuning the performance of CAR T cell immunotherapies

ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights

Non-viral vectors for chimeric antigen receptor immunotherapy

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19

[Chimeric antigen receptors in oncology: clinical applications and new developments]

Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and Accessibility

From bench to bedside: the history and progress of CAR T cell therapy

CAR-T cell therapy in India requires a paradigm shift in training, education and health care processes

Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?

Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells